AKRO 25.14 (+4.71%)
US00973Y1082BiotechnologyBiotechnology

Akero Therapeutics (AKRO) Stock Highlights

25.14 | +4.71%
2025-01-20 03:38:30
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The companys product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Statistics

Range Today
24.05 25.63
Volume Today 1.23M
Range 1 Year
15.32 37
Volume 1 Year 212.71M
Range 3 Year
7.52 58.38
Volume 3 Year 642.85M
Range 10 Year
7.52 58.38
Volume 10 Year 780.46M

Highlights

Market Capitalization 1.75B (small)
Floating Shares 55.41M
Current Price 25.14
Price To Earnings -6.14
Price To Book 2.37
Earnings Per Share -3.96
Payout Ratio 0%

Performance

Latest +4.71%
1 Month -13.61%
3 Months -19.01%
6 Months -6.99%
1 Year +16.17%
3 Years +15.11%
5 Years +27.03%
10 Years +55.57%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.